Humana (NYSE:HUM) PT Raised to $400.00 at Truist Financial

Humana (NYSE:HUM) had its price objective boosted by Truist Financial from $355.00 to $400.00 in a research note issued on Monday, Benzinga reports. The brokerage currently has a “hold” rating on the insurance provider’s stock. Truist Financial’s price target would indicate a potential upside of 1.11% from the stock’s previous close.

Several other analysts have also issued reports on HUM. Cantor Fitzgerald restated a “neutral” rating and issued a $360.00 price objective on shares of Humana in a research note on Wednesday, June 12th. UBS Group cut their price objective on Humana from $334.00 to $326.00 and set a “neutral” rating on the stock in a report on Thursday, April 25th. Oppenheimer cut their target price on Humana from $415.00 to $370.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. The Goldman Sachs Group cut their target price on Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a report on Wednesday, April 3rd. Finally, Wells Fargo & Company lowered their price objective on Humana from $413.00 to $350.00 and set an “overweight” rating for the company in a research report on Monday, April 8th. Fourteen analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $402.05.

Humana Stock Up 3.0 %

HUM stock opened at $395.60 on Monday. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.67 and a quick ratio of 1.67. The stock has a market capitalization of $47.67 billion, a P/E ratio of 24.63, a P/E/G ratio of 2.21 and a beta of 0.51. The business has a 50-day moving average of $358.11 and a 200-day moving average of $346.61. Humana has a fifty-two week low of $298.61 and a fifty-two week high of $530.54.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 24th. The insurance provider reported $7.23 earnings per share for the quarter, topping the consensus estimate of $6.12 by $1.11. The company had revenue of $29.61 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 17.76% and a net margin of 1.82%. Humana’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $9.38 earnings per share. On average, sell-side analysts anticipate that Humana will post 16.27 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Humana

A number of hedge funds and other institutional investors have recently bought and sold shares of HUM. Rakuten Securities Inc. purchased a new position in Humana in the fourth quarter worth $25,000. Gradient Investments LLC boosted its holdings in Humana by 200.0% in the fourth quarter. Gradient Investments LLC now owns 60 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 40 shares during the last quarter. Cetera Trust Company N.A purchased a new position in shares of Humana during the 4th quarter worth $28,000. Private Wealth Management Group LLC purchased a new position in shares of Humana during the 4th quarter valued at $32,000. Finally, Riverview Trust Co bought a new stake in Humana in the 2nd quarter valued at $44,000. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.